Welcome back. The previous lesson showed that slowing gastric emptying can spread nutrient delivery over time, but it does not fully explain why eating stops. This lesson follows information from the gut into the nervous system. You will use two gut–brain diagrams to distinguish signals that help end a meal from those that help you remain satisfied afterward, and to see why a GLP-1 medicine does more than simply keep food in the stomach.
Three routes into a feeding network
Satiation is the process that brings an ongoing meal to an end. Satiety is the reduced drive to eat between meals. They overlap, but they are not interchangeable: a signal might change meal size, the interval before the next meal, or both.
After food enters the gut, intestinal cells release GLP-1. Some of this short-lived signal acts locally, including on sensory pathways connected to the vagus nerve. Vagal afferents carry information from the body toward the nucleus of the solitary tract, or NTS, in the brainstem. The stomach also sends stretch-related information along vagal pathways. The NTS integrates incoming information about a meal and communicates with other regions involved in feeding.
There are two further routes to keep distinct. Neurons in and around the NTS make their own GLP-1, which can act within brain circuits. Meanwhile, a persistent GLP-1 receptor agonist can reach and activate receptors in certain accessible brain regions, as well as receptors outside the brain. Natural gut GLP-1, brain-produced GLP-1, and a medicine use the same receptor, but they do not arrive at it by identical routes or on identical timescales.
Watch GLP-1s Don’t Just Affect Your Appetite—They Affect Your Brain by Susan Brian MD for an orientation to these routes:
GLP-1s Don’t Just Affect Your Appetite—They Affect Your Brain
The video distinguishes gut-produced GLP-1, brain-produced GLP-1, and longer-lasting medicines. Use it to locate the vagus, brainstem, and regions accessible to circulating signals.
Watch the three sources for the distinction between gut, brain, and drug signals. In the vagal route, focus on how a gut signal can reach the brainstem without the GLP-1 molecule itself crossing into the brain. Watch accessible regions for the blood–brain barrier and area postrema, then brain-derived GLP-1 for the separate neural source. Finish with drug pathways, noting that a medicine need not reach every neuron whose activity it ultimately changes.
The diagrams and video are maps of possible routes, not a claim that each route contributes equally to every medicine’s effect. In particular, activating receptors on vagal sensory neurons is one way to influence gut–brain communication, but evidence from animal studies indicates that these receptors are not indispensable for most of the weight-loss effects tested with liraglutide or semaglutide.

Read the anatomical account in the Journal of Clinical Investigation review GLP-1 Physiology and Pharmacology Along the Gut–Brain Axis:
JCI - GLP-1 physiology and pharmacology along the gut-brain axis
The review identifies where the relevant receptors and neurons are found and adds qualifications that a simple diagram cannot show.
In “Basic anatomy of the GLP-1 system,” begin with the paragraph opening “In the peripheral nervous system.” Read the vagal account through its final example of another sensory circuit. Then find the following paragraph and read the NTS distinction: neurons that produce GLP-1 are not necessarily neurons on which the medicine acts. Finally, in the paragraph beginning “Of note, several of the central populations,” read the accessible regions through its end. Focus on why access to selected regions is different from unrestricted access to the entire brain.
From brainstem signals to a decision to stop eating
Return to the right-hand side of the first diagram. It places the brainstem between bodily signals and wider feeding networks. Within it, the NTS receives sensory information about the gut. Nearby, the area postrema can sense certain circulating substances because its barrier to blood-borne signals differs from that of most brain tissue. GLP-1 receptor activation in these regions can influence other neurons even when a drug does not directly reach those neurons.
The left-hand enlargement shows part of the hypothalamus, which helps integrate bodily state with feeding behavior. In its arcuate nucleus (ARC), POMC neurons generally participate in feeding-suppressing pathways, while AgRP neurons generally participate in hunger-promoting pathways. POMC-related signalling can engage circuits involving the paraventricular nucleus—labelled PVN in the first image and often called PVH. Those are two names for the same hypothalamic region.
This gives you a useful way to read the figure: GLP-1 receptor activation can shift activity within a network that weighs signals favoring continued eating against signals favoring meal termination. It would be too strong, however, to read the drawing as “the drug directly switches on every POMC neuron and switches off every AgRP neuron.” Animal studies show direct activation of some receptor-bearing POMC neurons, while inhibition of AgRP neurons can be indirect, through other cells and circuits. Likewise, the arcuate nucleus participates in feeding regulation but does not appear to be the sole, or necessarily the principal, site of a medicine’s weight-loss effect.
Read the relevant evidence in the same review:
JCI - GLP-1 physiology and pharmacology along the gut-brain axis
This section connects the anatomical map to experiments testing which receptor-bearing brain regions matter for drug-induced feeding suppression.
Under “GLP-1 pharmacology and the gut-brain axis,” find the subsection “Anorectic effects.” Read the brainstem findings, from the paragraph beginning “GLP-1RAs induce weight loss” through its conclusion about NTS receptors. Then, in the paragraph beginning “Most but not all studies suggest,” locate “Within the ARC” and read the arcuate findings to the paragraph’s end. Track the difference between a neuron responding directly to a drug and a neuron changing activity downstream.
Fullness is not the same as feeling ill
A smaller meal can result from comfortable satiation, but reduced eating can also accompany nausea or aversion. Both outcomes may follow GLP-1 receptor activation; they should not be treated as the same experience.
The second diagram makes this distinction visible. It depicts an NTS-associated route toward the hypothalamus for non-aversive satiety, alongside an area postrema-associated route toward the parabrachial nucleus for aversive responses. These are proposed circuit distinctions drawn largely from animal experiments, not a way to infer exactly what a particular person feels or which pathway accounts for their weight change.

Read the review’s account of the experiments behind that distinction:
JCI - GLP-1 physiology and pharmacology along the gut-brain axis
The review explains why satiety and aversion can be separated experimentally, while also showing that their roles in sustained weight loss are not fully settled.
Under “GLP-1 pharmacology and the gut-brain axis,” locate the subsection “Aversive effects.” Start at “Within the brainstem” and read the circuit comparison through the paragraph’s end. Pay particular attention to the difference between short-term feeding responses and results from experiments examining longer-term weight loss.
This also clarifies the link to gastric emptying from the previous lesson. A stomach that empties more slowly may contribute to sensations arising during and after a meal, but delayed emptying is not a complete explanation of reduced food intake. Brainstem and hypothalamic signalling can affect feeding independently of simply leaving food in the stomach. Conversely, nausea is not proof that appetite regulation is “working better.” The precise contribution of each circuit to sustained benefits and adverse experiences in humans remains uncertain.
Key takeaways
A gut–brain diagram is most useful when read as a network map rather than one continuous chain. Meal-related signals can reach the brainstem through vagal afferents; brainstem regions integrate these inputs and communicate with hypothalamic feeding circuits. GLP-1 receptors are present at several points, and longer-lasting medicines can engage selected accessible brain regions without entering every part of the brain. The hypothalamus helps shape feeding behavior, but neither one nucleus nor slower gastric emptying explains the whole effect.
Keep the terms separate: satiation helps end the current meal, satiety reduces eating drive afterward, and aversion involves an unpleasant response. The next lesson turns from these meal-regulating circuits to proposed effects on dopamine-linked reward pathways, where distinguishing animal mechanisms from demonstrated human effects becomes especially important.